Project Details
| Status | Active |
|---|---|
| Effective start/end date | 03/29/24 → 11/14/26 |
Funding
- Alexion Pharmaceuticals Incorporated: $277,174.45
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Skopicki, Hal A (PI)
- Riquelme, Luis Angel (CoPI)
- Borriello, Caitlin (CoPI)
- Reilly, Peter (CoPI)
Project: Research